copper
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | PARAGARD T 380A | — | 1989-07-17 – 2024-06-28 | fda.gov ↗ |
| Approved | US (FDA) | PARAGARD T 380A | — | 1984-11-15 | fda.gov ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02963051 | Jul 2017 → Dec 2018 | prostate cancer | Daniel George, MD | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03142178 | Apr 2017 → Jan 2018 | arthropathy | CDA Research Group, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01777919 | Jan 2027 → Jan 2029 expected | glioblastoma | Olympion Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04265274 | Jan 2020 → Jan 2022 | breast cancer | National Cancer Institute, Slovakia | Withdrawn | No outcome recorded |
| Phase 2 | NCT02062034 | Feb 2011 → Nov 2013 | diabetic retinopathy, type 2 diabetes mellitus | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT00963131 | Dec 2004 → Dec 2008 | central serous chorioretinopathy | Prince of Songkla University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03702374 | Sep 2018 → Nov 2020 | diabetic retinopathy | University of Guadalajara | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07054697 | Jan 2017 → Dec 2024 | autism spectrum disorder | Aditi Chadha | Completed | No outcome recorded |
| Phase 4 | NCT07161804 | Dec 2016 → Dec 2024 | autism spectrum disorder | Holistic Homoeopathic Clinic and Research Center | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 0 | NCT03151772 Background | Jan 2018 → Sep 2020 | glioblastoma | Sahlgrenska University Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT03230539 Background | May 2017 → Jan 2018 | — | Population Council | Unknown | No outcome recorded |
| Phase 1/2 | NCT01259050 Background | Oct 2010 → Jan 2012 | amyotrophic lateral sclerosis | Phoenix Neurological Associates, LTD | Completed | No outcome recorded |
| Phase 2 | NCT04071977 Comparator | Mar 2020 → Oct 2021 | diabetes mellitus, diabetic retinopathy | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT03323346 Background | Sep 2017 → Oct 2025 | breast cancer | The Institute of Molecular and Translational Medicine, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT07758335 Comparator | Jul 2025 → Mar 2027 expected | ulcerative colitis | National Hepatology & Tropical Medicine Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT05677126 Comparator | Aug 2024 | — | American Regent, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04309669 Background | Nov 2020 → Oct 2023 | anemia | Laboratoire Innotech International | Completed | No outcome recorded |
| Phase 4 | NCT00431691 Comparator | Sep 2006 → Dec 2007 | escherichia coli infection, retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00914576 Comparator | Apr 2011 → Jul 2013 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | copper | “Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance...” NCT03323346 ↗16“It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗ “This study aims to assess the onset-of-action of oral liquid solution of ferrous gluconate, copper and manganese gluconate in adults with moderate iron deficiency anaemia.” PMID 41277915 ↗ Nov 2025 “(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks” NCT02062034 ↗ “containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg” NCT00914576 ↗ “200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively” NCT03151772 ↗ “The active pharmaceutical ingredient is copper.” NCT03142178 ↗ “intrauterine systems Delivering Copper” NCT03230539 ↗ “copper (copper sulfate 1 mg)” NCT04071977 ↗ “copper 1000 mcg” NCT07758335 ↗ “copper 0.4mg” NCT00431691 ↗ |
| Known as | Copper Star | “Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper.” NCT03323346 ↗ |
| Known as | copper sulfate | “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗1“copper (copper sulfate 1 mg)” NCT04071977 ↗ |
| Known as | CUPRUM METALLICUM | “Thuja officinalis Vaccininum Causticum Argentum nitricum Tuberculinum Stramonium Staphysagria Arum triphyllum Bacillinum Cina Carcinocin Cuprum Metallicum Ambera grisea...” NCT07161804 ↗1“CUPRUM METALLICUM” NCT07054697 ↗ |
| Known as | STARLIFE | “Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper.” NCT03323346 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “homeopathic treatment” NCT07161804 ↗ |
| Route | Oral | “daily of oral, all of them in one Tablet for 24 weeks” NCT02062034 ↗ |